EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug
阿斯利康阿斯利康(US:AZN) Reuters·2026-05-22 18:45

公司动态 - 欧洲药品管理局委员会于周五对阿斯利康的实验性乳腺癌药物camizestrant给出了积极意见 [1] 产品研发 - 阿斯利康的实验性乳腺癌药物camizestrant的研发取得了积极进展 [1]

EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug - Reportify